Amicus Therapeutics' Upcoming Investor Engagements
Amicus Therapeutics today announced its management team is gearing up to participate in significant investor conferences this November. The company's commitment to advancing solutions for rare diseases continues to shine through these strategic engagements.
Investor Conferences Overview
In mid-November, Amicus Therapeutics will take part in two prominent investor conferences. The first is the Guggenheim Healthcare Innovation Conference, scheduled for Tuesday at 2:30 p.m. ET. This event takes place in Boston and serves as a key opportunity to network and share insights with investors and industry leaders.
Guggenheim Conference Highlights
The Guggenheim Healthcare Innovation Conference is known for bringing together innovative companies and investors focusing on healthcare advancements. Amicus Therapeutics, recognized for its pioneering work, looks to showcase its latest developments and interact with the investment community.
Jefferies London Healthcare Conference
Following the Guggenheim conference, Amicus will present at the Jefferies London Healthcare Conference on Tuesday at 8:00 a.m. GMT. This event provides a platform to discuss its initiatives and successes within the global market.
Additional Engagements
Amicus Therapeutics will also attend the J.P. Morgan Equity Opportunities Forum the day after the Guggenheim conference. This adds dimension to their outreach, enabling them to engage with both equity and healthcare investment professionals.
About Amicus Therapeutics
Amicus Therapeutics is a dedicated biotech firm focused on developing innovative and high-quality medicines tailored for people affected by rare diseases. The company's strong emphasis on patient needs drives its commitment to creating first- or best-in-class therapies. This focus has propelled Amicus to a significant position within the biotechnology industry and showcases its promise to stakeholders.
Innovative Medicines Pipeline
Amicus Therapeutics is recognized for its relentless pursuit of novel treatments. The organization's pipeline includes various promising therapies aimed at addressing unmet medical needs in rare disease populations. The team continuously works to expand its offerings while prioritizing the well-being of patients.
Contact Information
If you wish to learn more about Amicus Therapeutics or its upcoming events, please reach out as follows:
For Investors:
Contact: Andrew Faughnan
Vice President, Investor Relations
Email: afaughnan@amicusrx.com
Phone: (609) 662-3809
For Media Inquiries:
Contact: Diana Moore
Head of Global Corporate Affairs and Communications
Email: dmoore@amicusrx.com
Phone: (609) 662-5079
Frequently Asked Questions
What investor conferences is Amicus Therapeutics attending?
Amicus Therapeutics will participate in the Guggenheim Healthcare Innovation Conference and the Jefferies London Healthcare Conference in November.
How does Amicus Therapeutics contribute to healthcare?
Amicus Therapeutics focuses on developing innovative medicines for individuals with rare diseases, aiming to improve patient outcomes.
Who can I contact for investor relations at Amicus Therapeutics?
You can contact Andrew Faughnan at afaughnan@amicusrx.com for any investor relations inquiries.
What is the focus of Amicus Therapeutics?
Amicus Therapeutics specializes in creating high-quality medicines for rare diseases, prioritizing patient needs and innovative solutions.
When will Amicus present at the Guggenheim conference?
Amicus Therapeutics' presentation at the Guggenheim Healthcare Innovation Conference is scheduled for November 12 at 2:30 p.m. ET.